80918-66-7

Basic information

• Product Name: (S)-3-Aminopiperidine
• Synonyms: (S)-3-AMINOPIPERIDINE;3-Piperidinamine,(3S)-(9CI)
• CAS NO: 80918-66-7
• Molecular Formula: C₅H₁₂N₂
• Molecular Weight: 100.16
• EINECS: 1312995-182-4
• Product Categories: VARIOUSAMINE;Chiral chemicals
• Mol File: 80918-66-7.mol

Chemical Properties

• Boiling Point: 157.9°C at 760 mmHg
• Flash Point: 52.7°C
• Appearance: /
• Density: 0.91g/cm³
• Vapor Pressure: 2.69mmHg at 25°C
• Refractive Index: 1.456
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.49±0.20(Predicted)
• CAS DataBase Reference: (S)-3-Aminopiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Aminopiperidine(80918-66-7)
• EPA Substance Registry System: (S)-3-Aminopiperidine(80918-66-7)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• RIDADR: UN2735
• Hazardous Substances Data: 80918-66-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Aminopiperidine is used as a key building block for the synthesis of pan-JNK inhibitors, which are crucial in the treatment of Huntington's disease. These inhibitors target the c-Jun N-terminal kinases (JNKs), a family of protein kinases involved in the regulation of cell survival, apoptosis, and inflammation. By modulating the activity of JNKs, pan-JNK inhibitors can potentially alleviate the symptoms and slow down the progression of Huntington's disease.
Additionally, (S)-3-Aminopiperidine can be utilized in the development of other therapeutic agents targeting different diseases and conditions, given its versatile chemical properties and potential for further functionalization. Its applications in the pharmaceutical industry are vast, making it a valuable compound for drug discovery and medicinal chemistry research.

InChI:InChI=1/C5H12N2/c6-5-2-1-3-7-4-5/h5,7H,1-4,6H2/t5-/m0/s1

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 34294-79-6 (S)-(-)-3-aminopiperidin-2-one 
• 94695-52-0 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 
• 54012-73-6 3-aminopiperidine 
• 3184-13-2 L-ornithine hydrochloride 
• 16682-12-5 D-ornithine hydrochloride 
• 42538-31-8 (3S)-3-aminopiperidin-2-one hydrochloride 
• 2530-26-9 3-nitropyridine 
• 4318-76-7 pyridine-2,5-diamine 
• 64-17-5 ethanol 
• 40216-82-8 methyl (S)-2,5-diaminopentanoate dihydrochloride 

Downstream Products

• 63921-21-1 3-amino-1-phenylpiperidine 
• 100240-05-9 3-(phenylamino)piperidine 
• 62813-09-6 3-(phthalimido)piperidine 
• 127294-73-9 (R)-piperidin-3-ylamine 
• 54012-73-6 (S)-piperidin-3-amine 
• 1247828-69-8 C₁₁H₁₅N₃O₂ 
• 334618-23-4 3-(R)-aminopiperidine dihydrochloride 
• 334618-23-4 (S)-(-)-3-aminopiperidine dihydrochloride 

Relevant articles and documents

One-pot synthesis of cyclohexylamine and: N -aryl pyrroles via hydrogenation of nitroarenes over the Pd0.5Ru0.5-PVP catalyst

The direct synthesis of cyclohexylamine via the hydrogenation of nitrobenzene over monometallic (Pd, Ru or Rh) and bimetallic (PdxRu1-x) catalysts was studied. The Pd0.5Ru0.5-PVP catalyst was the most effective catalyst for this reaction. The catalyst can be reused and applied for the synthesis of N-aryl pyrroles and quinoxalines from nitrobenzenes.

Substituted xanthine compound and its preparation and use (by machine translation)

The invention discloses substituted xanthine compounds, a preparation method and applications thereof, and specifically relates to compounds represented by the formula (I), stereo isomers and pharmaceutically acceptable salts thereof, wherein the R1 and R2 are defined in the description. The invention also relates to a pharmaceutical composition containing the compounds, an application of the pharmaceutical composition in preparation of drugs for treating diseases or symptoms caused by high activity of DPP-IV or overexpression of DPP-IV, and a method using the pharmaceutical composition to treat related diseases. The provided compounds can effectively inhibit the activity of DPP-IV.

Novel chiral derivatizing agents for 1H NMR determination of enantiomeric purities of carboxylic acids

(S)-4-(3-Aminopyrrolidin-1-yl)coumarin (1), (S)-4-(3-aminopiperidin-1-yl)coumarin (4), and (S)-4-(3-aminoazepan-1-yl)coumarin (7), prepared from 4-chlorocoumarin and (S)-pyrrolidin-3-amine, (S)-piperidin-3-amine, and (S)-azepan-3-amine, respectively, were proven to be versatile and reliable 1H NMR optical purity determination agents for chiral carboxylic acids.

Dielectrically controlled resolution (DCR) of 3-aminopiperidine via diastereomeric salt formation with N-tosyl-(S)-phenylalanine

A useful key intermediate for the dipeptidyl peptidase-4 (DPP-4) inhibitor, 3-aminopiperidine 1, was successfully resolved with an enantiomerically pure resolving agent, N-tosyl-(S)-phenylalanine 2, to give both stereoisomers (R)-1 and (S)-1 as a less-sol

A protection strategy substantially enhances rate and enantioselectivity in ω-transaminase-catalyzed kinetic resolutions

The kinetic resolution of 3-aminopyrrolidine (3AP) and 3-aminopiperidine (3APi) with ω-transaminases was facilitated by the application of a protecting group concept. 1-N-Cbz-protected 3-aminopyrrolidine could be resolved with >99% ee at 50% conversion, the resolution of 1-N-Boc-3-aminopiperidine yielded 96% ee at 55% conversion. The reaction rate was up to 50-fold higher by using protected substrates. Most importantly, enantioselectivity increased remarkably after carbamate protection compared to the unprotected substrates (86 vs. 99% ee). Surprisingly, benzyl protection of 3AP had no influence on enantioselectivity. A possible explanation for this observation could be the different flexibility of the benzyl- or carbamate-protected 3AP as confirmed by NMR spectroscopy.

8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS

The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.

METHOD FOR PRODUCING 3-AMINOPIPERIDINE DIASTEREOMER

A method for increasing the enantiomeric purity of a desired enantiomer of 3- aminopiperidine comprising: providing a composition containing (i?)-3-arninopiperidine and (jS)-3-aminopiperidine; combining the composition with a resolving agent selected from

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part III: Synthesis of potent antagonists with αvβ3/α IIbβ3 dual activity and improved water solubility

In order to optimize our novel integrin αvβ 3/αIIbβ3 dual antagonists, spatial screening at the N-terminus was performed. The αvβ 3 antagonistic activity varied depending on the space that was occupied by the N-terminus, but high potency against αIIbβ 3 was well maintained. The (3S)-aminopiperidine analogue had the strongest activity against αvβ3, and the S isomer at piperidine was more potent than the R isomer. Compounds selected on the basis of SAR analysis of a novel lead compound showed acceptable early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and sufficient water solubility for use as infusion drugs. Docking studies with the αvβ3 receptor were performed to confirm the SAR findings.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too

METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES

The invention relates to an improved method for producing enantiomer-free 8-(3-amino-piperidin-1-yl)-xanthines.